Danish Jabbar, MD
Internal Medicine · Saint Louis, MONPI 1114183019
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 1,352 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,352 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- AstraZeneca$2K
- Novo Nordisk$1K
- GSK$1K
- Novo Nordisk AS$850
- Lilly USA, LLC$783
- plus $12K from 54 others
Across 697 payments — averaging $699.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$488K
- Novo Nordisk$50
What the payments were for
- Travel & lodging$5753%
- Food & beverage$21,85996%
- Education$1521%
- Gifts$590%
- Entertainment$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,661 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 41 | $151,943 |
| EliquisApixaban | 245 | $148,753 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 159 | $129,911 |
| XareltoRivaroxaban | 271 | $122,840 |
| RexultiBrexpiprazole | 74 | $93,968 |
| JardianceEmpagliflozin | 182 | $91,918 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 101 | $68,979 |
| FarxigaDapagliflozin Propanediol | 100 | $67,158 |
| OzempicSemaglutide | 59 | $66,183 |
| LinzessLinaclotide | 107 | $62,738 |
| JanuviaSitagliptin Phosphate | 63 | $56,252 |
| EntrestoSacubitril/Valsartan | 111 | $54,677 |
| OxycontinOxycodone Hcl | 48 | $52,510 |
| TrulicityDulaglutide | 51 | $51,327 |
| UbrelvyUbrogepant | 28 | $48,938 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Xarelto | $535 | $274,782312 claims |
| AbbVieLinzess, Ubrelvy, Qulipta, Vraylar | $5,198 | $178,819183 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,007 | $166,298232 claims |
| PfizerEliquis, Nurtec Odt | $544 | $165,532260 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $1,926 | $153,114260 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $712 | $141,592249 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $573 | $93,96874 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $783 | $85,88177 claims |
| Novo NordiskOzempic | $1,080 | $66,18359 claims |
| MerckJanuvia | $347 | $56,25263 claims |
| NovartisEntresto | $386 | $54,677111 claims |
| Astellas Pharma US IncMyrbetriq | $333 | $30,67580 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Saint Louis
- Vinay KamatSaint Louis$191K
- David PrelutskySaint Louis$182K
- Tracy NorfleetSaint Louis$132K
- Paul OlivoSaint Louis$98K
- William SummersSaint Louis$93K
- Mark ScheperleSaint Louis$89K
- Shiyang ZhangSaint Louis$45K
- Bernard McGuireSaint Louis$37K
- Daniel GaitanSaint Louis$34K
- Nathan FarkasSaint Louis$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.